Scott Lee
Associate Professor
Medicine
Division of Gastroenterology
Director, Clinical Inflammatory Bowel Disease Program

Faculty Information

Biography
Scott Lee, M.D., is a board certified gastroenterologist at the Digestive Health Center at UW Medical Center and a UW associate professor of Medicine and Gastroenterology.

Dr. Lee has expertise in inflammatory bowel disease (IBD). He strives to provide patients with the best objective evidence-based medical information using the most up to date medical research and work in partnership with each patient to choose the treatment options that is individualized to each patient.

Dr. Lee earned his M.D. at Jefferson Medical College in Philadelphia. He is a member of the Crohn's Colitis Foundation of America, American Gastroenterology Association, American College of Gastroenterology and American Society of Gastrointestinal Endoscopy. He has participated in more than 100 clinical trials in inflammatory bowel diseases (IBD) and continues to have an active clinical research program.
 
Board Certifications:
  • Gastroenterology, 2000, American Board of Internal Medicine
Education & Training: 
Fellowship in Gastroenterology
University of Washington
Residency in Internal Medicine
University of Colorado HSC
Internship in Internal Medicine
University of Colorado HSC
Medical Education
Jefferson Medical College
1994
Research & Clinical Interests
Clinical Interests: 
  • Gastroenterology (Digestive)
  • Telehealth Services
Publications
Publications: 
Nguyen P, Lee SD, Castell DO. Evidence of gender differences in esophageal pain threshold. Am J Gastroenterol. 1994; 90(6): 901-905. [Original work]
 
Lee SD, Haggitt RC, Kimmey MB. Squamous metaplasia of the rectum following argon plasma coagulation. Gastrointest Endosc. 2000; 52: 683-685. [Original work]
 
Rulyak SJ, Saunders MD, Lee SD. Hepatotoxicity associated with 6-thioguanine therapy for Crohn’s Disease. J Clin Gastro. 2003; 36(3): 234-237. [Original work]
 
Lee SD, Turgeon DK, Fritsche TR, Ko CW, Surawicz CS. Clinical correlation of toxin and common antigen EIA testing in patients with C. difficile disease. Am J Gastroenterol. 2003; 98(7): 1569-1572. [Original work]
 
Lee SD, Kearney DJ. A randomized controlled trial of gastric lavage for acute upper gastrointestinal bleeding. J Clin Gastroenterol. 2004; (38): 861-865. [Original work]
 
Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, for the Sargramostim in Crohn’s Disease Study Group (Lee SD, one of the members of this study group): Sargramostim for Active Crohn’s Disease. New Engl J Med 2005; 352:2193-2201. [Original work]
 
Cullinan C, Wheat C, Sewell C, Murphy C, Lee SD. Participation in a Multi-Center, Randomized, Double-Blinded, Sham-Controlled Apheresis Device Trial by Investigators from a Digestive Disease Center, A Single Center Experience. Journal of Clinical Apheresis. V21: 22, April 2006. [Original work]
 
Huebner SE, Dubois D, Lee SD, Saunders MD. Successful Endoscopic treatment of Bouveret’s syndrome with intracorporeal electrohydraulic lithotripsy. Gastrointestinal Endoscopy. 2007; 66 (1): 183-184. [Original work]
 
Ko CW, Riffle S, Shapiro JA, Saunders MD, Lee SD, Tung BY, Kuver R, Larson AM, Kowdley KV, Kimmey MB. Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Gastrointestinal Endoscopy. 2007; 65 (4):648-686. [Original work]
 
Etzel JP, Eng SC, Ko CW, Lee SD, Saunders MD, Tung BY, Kimmey MB, Kowdley KV. Complications after ERCP in patients with primary scleriosing cholangitis. 2007; 30:1-6. [Original work]
 
Schreiber S, Kareemi MK, Lawrance IC, Thomsen O, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, for the Certolizumab Pegol for Crohn’s Disease Study Group (Lee SD, one of the members of this study group) Maintenance Therapy with Certolizumab pegol for Crohn’s Disease. New Engl J Med 2007; 357: 239-50. [Original work]
 
Headstrom, PD, Rulyak, SJ, Lee SD. Prevalence of and Risk Factors for Vitamin B12 Deficiency in Patients with Crohn’s disease. Inflammatory Bowel Diseases, February 2008; 14(2):217-223. [Original work]
 
Sandborn WJ, Abreu MT, D’Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee SD, Rutgeerts P. Certolizumab Pegol in Patients With Moderate to Severe Crohn’s Disease and Secondary Failure to Infliximab. Clinical Gastroenterology and Hepatology. 2009, doi: 10.1016/j.cgh.2010.04.021. [Original work]
 
Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, Humphries TJ, for the Sargramostim in Crohn’s Disease Study Group (Lee SD, one of the members of this study group): Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn’s disease: a randomized, double-blind, placebo-controlled, phase 2 study. Gut 2009; 58; 1354-1362. [Original Work]
 
Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Scholmerich J, Panes J, Sandborn WJ for the PRECISE 2 Study Group (Lee SD, one of the members of this study group): Increased Response and Remission Rates in Short-Duration Crohn’s Disease with Subcutaneous Certolizumab Pegol: An Analysis of PRECISE 2 Randomized Maintenance Trial Data. Am J Gastroenterol 16 MAR 2010 advance online publication (doi:10.1038/ajg.2010.78) [Original Work]
 
Song K, Toweill D, Rulyak SJ, Lee SD. Novel Jumbo Biopsy Forceps for Surveillance of Inflammatory Bowel Disease: A Comparative Retrospective Assessment. Gastroenterology Research and Practice. Vol. 2011, Article ID 671659, 5 pages, 2011. Doi:10.1155/2011/671659. [Original work]
 
Wong AC, Lee SD. Long term therapy with sargramostim in a patient with Crohn’s Disease. Inflammatory Bowel Diseases, June 2011; 17(6):1447-1448. [Original work]
 
Harper JW, Welch MP, Sinanan MN, Wahbeh GT, Lee SD. Co-morbid diabetes in patients with Crohn’s Disease predicts a greater need for surgical intervention. Alimentary Pharmacology and Therapeutics. 2012, 35: 126-132. [Original work]*
 
Zisman TL, Bronner MP, Rulyak S, Kowdley KV, Saunders MD, Lee SD, Ko CW, Kimmey MB, Stevens A, Maurer J, Brentnall TA. Prospective Study of the Progression of Low-Grade Dysplasia in Ulcerative Colitis Using Current Cancer Surveillance Guidelines. Inflammatory Bowel Diseases, 2012. [Original work]
 
Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar;11(3):286-92. Epub 2012 Nov 28. [Original work]
 
Wahbeh GT, Suskind DL, Lee SD, Waldhausen JT, Murray KF. The pediatric pouch in inflammatory bowel disease: a primer for the gastroenterologist. Expert Review of Gastroenterology & Hepatology, March 2013, Vol. 7, No. 3, Pages 215-223. [Review]
 
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21. doi: 10.1056/NEJMoa1215739. [Original work]*
 
Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014 Jun; 8(6): 480-8. [Original work]*
 
Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. Alimentary Pharmacology and Therapeutics. 2014 August 22; 40: 903-916. [Original work]
 
Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W, Vermeire SA, Dewit O, Peeters H, Stehlik J, Vanasek T, Laharie D, Colombel JF, Bigard MA, Varga M, Zeher M, Novak J, Hunyady B, Salamon A, Racz I, Gionchetti P, Kohn A, Prantera C, Stokkers PC, Slomka M, Paradowski L, Arlukowicz T, Kuzela L, Baricky B, Hlavaty T, Vera MI, Panes J, Guardiola J, Probert C, Shaffer JL, Fleisher M, Pruitt RE, Sandborn WJ, Goff JS, Weber J, Bell RL, Zwick AH, Gutierrez A, Levine RH, Hanauer SB, Lavelle LA, Kottoor RK, Dryden GW Jr, Hardi R, Glorioso DV, Swaroop P, Lee SD, Patrick TJ, Scheinert S, Sninsky CA, Katz S, Noar MD, Gaspari MM, Gordon GL, Dalton TA, Homoky DE, Kilgore WR 3rd, Levien JA, Schneider HR, Moola SA, Kruger FC, Wright JP, Aboo N. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1485-93. [Original work]
 
Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R. Briakinumab for Treatment of Crohn’s Disease: Results of a Randomized Trial. Inflammatory Bowel Disease. 2015; 21: 1329-1340. [Original work]
 
Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Requeiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn’s disease: analyses from the 7-year PRECiSE 3 study. Alimentary Pharmacology and Therapeutics. 2015 Aug; 42 (3): 330-42. doi: 10.1111/apt.13251. [Original work]
 
Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Reinduction with Certolizumab Pegol in Patients with Crohn’s Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflammatory Bowel Diseases, 2016 Aug; 22 (8): 1870-80. [Original work]*
 
Afzali A, Park CJ, Zhu K, Hu JK, Sharma P, Sinanan MN, Lee SD. Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2016 Aug; 22 (8): 1887-1895. [Original work]
 
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 Nov; 375 (20): 1946-1960. [Original work]*
 
William J. Sandborn; Douglas C. Wolf; Gordana Kosutic; Gerry Parker; Stefan Schreiber; Scott D. Lee; Bincy Abraham; Anita Afzali; Razvan I. Arsenescu; Alexandra Gutierrez; Marshall Spearman; Jason Coarse; Brian G. Feagan. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Inflammatory Bowel Diseases, 2017 APR; 23 (7): 1047-1056. [Original work]
 
Debiec KE, Lee SD, Wahbeh GT, Amies Oelschlager AM.; Outcomes of Therapy for Vulvar Manifestation of Inflammatory Bowel Disease in Adolescents. J Pediatr Adolesc Gynecol. 2018 Apr;31(2):149-152. doi: 10.1016/j.jpag.2017.08.008. [Original work]
 
Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, Feagan BG.; Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Dig Dis Sci. 2018 Apr;63(4):825-833. doi: 10.1007/s10620-018-4971-1. [Original work]
 
Schreiber S, Siegel CA, Friedenberg KA, Younes ZH, Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, Sundy JS, Lee SD, Loftus EV Jr.; A phase 2, Randomized, Placebo-controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients with Moderately to Severely Active Crohn's Disease. J Crohns Colitis. 2018 May 29. doi: 10.1093/ecco-jcc/jjy070. [Original work]
 
Sandborn WJ, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Reinisch W, Hébuterne X, Park DI, Schreiber S, Nayak S, Ahmad A, Banerjee A, Brown LS, Cataldi F, Gorelick KJ, Cheng JB, Hassan-Zahraee M, Clare R, D'Haens GR.; Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. 2018 Oct;67(10):1824-1835. doi: 10.1136/gutjnl-2016-313457. [Original work]
 
Clark-Snustad KD, Singla A, Lee SD. Efficacy of Infliximab in Crohn’s Disease Patients with Prior Primary Nonresponse to Tumor Necrosis Factor Antagonists. Digestive Diseases and Sciences. 2019 Feb 28; doi: 10.1007/s10620-019-05490-0. [Original work]
 
Billington S, Shoner S, Lee SD, Clark-Snustad K, Pennington M, Lewis D, Muzi M, Rene S, Lee J, Nguyen T, Kumar V, Ishida K, Chen L, Chu X, Lai Y, Salphati L, Hop C, Xiao G, Liao M, and Unadkat J. PET Imaging of [11C] Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporine A. Clinical Pharmacology & Therapeutics. 2019 May 18; doi:10.1002/cpt.1506. [Original work]
 
Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J.; Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2019 Nov 9. pii: S0016-5085(19)41526-6. doi: 10.1053/j.gastro.2019.10.035. [Original work]
 
Lee SD, Singla A, Rulyak SJ, Clark-Snustad K. Double-blind, randomised, placebo controlled crossover trial to evaluate the clinical efficacy of rifaximin in patients with moderate to severe active Crohn’s disease. GastroHep. 2020 Aug 1; 00:1–8. https://doi.org/10.1002/ygh2.416 [Original work]
 
Lee SD, Singla A, Clark‐Snustad K. Standard and modified vedolizumab dosing is effective in achieving clinical and endoscopic remission in moderate‐severe Crohn’s disease. GastroHep. 2020 Dec 21. https://doi.org/10.1002/ygh2.438.
 
Kamp, K, Clark-Snustad, K, Barahimi, M, Lee, SD.. Relationship between fatigue and endoscopic disease activity in inflammatory bowel disease. Gastrointestinal Nursing. 2021. [Chart Review] (Accepted)
 
Barahimi M, Lee SD, Clark-Snustad K. (Accepted). Case Report: Pustular Rash in Crohn's Patient on Ustekinumab Raises Concern for Drug Induced Paradoxical Psoriasis. Case Reports in Gastroenterology. 2021. [Case Report] (Accepted)